Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 6:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
Acetazolamide, Placebo
Drug
Lead sponsor
Vishwajit Nimgaonkar, MD PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Schizophrenia
Interventions
Clozapine augmented with atomoxetine up to 40 mg or placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Schizophrenia, Treatment-resistant Schizophrenia, Schizoaffective Disorder
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 50 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Schizophrenia
Interventions
Olanzapine, Clozapine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
10 Years to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
3
States / cities
Dix Hills, New York • Glen Oaks, New York • The Bronx, New York
Terminated Not applicable Interventional Results available

Treating Refractory Schizophrenia With rTMS

NCT02242578
Conditions
Schizophrenia
Interventions
1 Hz rTMS, 10 Hz rTMS
Device
Lead sponsor
Seton Healthcare Family
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Austin, Texas
Conditions
Obesity, Ketogenic Dieting, Metabolic Syndrome, Bipolar Disorder, Schizophrenia, Weight Gain, Psychotropic Agents Causing Adverse Effects in Therapeutic Use, Brain Metabolic Disorder
Interventions
LCHF, Ketogenic Diet
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Stanford, California
Conditions
Treatment-resistant Schizophrenia
Interventions
Lu AF35700, Risperidone, Olanzapine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Conditions
Metabolic Syndrome
Interventions
Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan, As selected by community physician
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
19 Years to 79 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Glen Oaks, New York
Conditions
Weight Gain, Sialorrhea
Interventions
FazaClo (clozapine, USP) ODT
Drug
Lead sponsor
Azur Pharma, Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Costa Mesa, California • Gastonia, North Carolina
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Obesity, Metabolic Syndrome
Interventions
olanzapine and melatonin
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Conditions
Schizophrenia
Interventions
Quetiapine, Risperidone, Fluphenazine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Catonsville, Maryland
Conditions
Schizophrenia
Interventions
Risperidone, Olanzapine, Lu AF35700
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
1,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
49
States / cities
Bellflower, California • Cerritos, California • Costa Mesa, California + 39 more
Conditions
Schizophrenia, Auditory Hallucination, Treatment-resistant Schizophrenia
Interventions
stg-rt-fMRI-Neurofeeback, sham-rt-fMRI-Neurofeedback
Other
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Brockton, Massachusetts
Recruiting Not applicable Interventional

Deep Brain Stimulation for Psychosis

NCT06257056
Conditions
Treatment-Refractory Schizophrenia
Interventions
Abbott Laboratories Infinity™ implantable deep brain stimulation system
Device
Lead sponsor
Bradley Lega
Other
Eligibility
22 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Schizophrenia, Schizophrenia and Related Disorders, Bipolar Disorder, Bipolar and Related Disorders, Major Depressive Disorder, Major Depression Severe, Ketogenic Dieting, Ketosis, Metabolic Disease, Metabolic Syndrome
Interventions
LCHF Ketogenic Diet, Diet-as-Usual (DAU)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Treatment-resistant Schizophrenia
Interventions
Insightec Exablate Neuro MR-guided focused ultrasound transducer
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
New York, New York
Conditions
Treatment-resistant Schizophrenia
Interventions
Evenamide 15 mg bid, Placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 2 more
Conditions
Schizophrenia, Schizo Affective Disorder, Treatment-resistant Schizophrenia
Interventions
Telmisartan Pill
Drug
Lead sponsor
Xiaoduo Fan
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Worcester, Massachusetts
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Placebo-Controlled, Cross-Over Trial of Aripiprazole

NCT00351936
Conditions
Schizophrenia
Interventions
Aripiprazole, placebo
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1Phase 2 Interventional Results available

Electroconvulsive Therapy in Clozapine Refractory Schizophrenia

NCT00042224
Conditions
Schizophrenia
Interventions
Electroconvulsive Therapy (ECT), Clozapine
Procedure · Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Glen Oaks, New York
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Completed Not applicable Interventional Results available

Salsalate for Insulin Resistance in Schizophrenia

NCT01182727
Conditions
Schizophrenia, Insulin Resistance
Interventions
salsalate
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland
Conditions
Schizo Affective Disorder, Schizophrenia
Interventions
L-arginine, Sapropterin Dihydrochloride
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Schizophrenia, Diabetes, Metabolic Syndrome, Hyperglycemia
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
New York, New York